Published in Blood on February 15, 2001
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med (2005) 2.54
4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol (2007) 1.57
Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody. Biol Blood Marrow Transplant (2012) 1.47
Identification of HLA-A*2402-restricted HCMV immediate early-1 (IE-1) epitopes as targets for CD8+ HCMV-specific cytotoxic T lymphocytes. J Transl Med (2009) 1.24
Ex vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR). J Transl Med (2003) 1.01
Human dendritic cells and transplant outcome. Transplantation (2008) 0.92
Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther (2010) 0.91
Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry. Front Immunol (2013) 0.90
Human Cytomegalovirus (HCMV) - Revised. Transfus Med Hemother (2010) 0.83
Accelerating immune reconstitution after hematopoietic stem cell transplantation. Clin Transl Immunology (2014) 0.81
CMV-specific T cell isolation from G-CSF mobilized peripheral blood: depletion of myeloid progenitors eliminates non-specific binding of MHC-multimers. J Transl Med (2014) 0.79
Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts. J Immunother (2016) 0.75
Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med (1994) 5.28
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2001) 2.00
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 1.93
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia (2009) 1.29
Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant (2008) 1.14
Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood (1996) 1.08
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant (2008) 1.08
Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation (1989) 1.03
Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant (2004) 0.98
Development and evaluation of an internally controlled semiautomated PCR assay for quantification of cell-free cytomegalovirus. J Med Virol (2002) 0.97
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy (2001) 0.93
Prevention of graft-versus-host disease by ex vivo T cell depletion: reduction in graft failure with augmented total body irradiation. Leukemia (1988) 0.92
Nerve allograft response: a quantitative immunological study. Neurosurgery (1982) 0.92
Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol (2000) 0.91
The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant (2005) 0.90
Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transplant (2004) 0.90
An unusual case of intrapulmonary granulocytic sarcoma presenting as interstitial pneumonitis following allogeneic bone marrow transplantation for acute myeloid leukaemia and responding to donor lymphocyte infusion. Bone Marrow Transplant (1999) 0.88
Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. Leukemia (2002) 0.87
Human herpesvirus-7 infection of the CNS with acute myelitis in an adult bone marrow recipient. Bone Marrow Transplant (2002) 0.84
Cavernosal arterial insufficiency is a major component of erectile dysfunction in some recipients of high-dose chemotherapy/chemo-radiotherapy for haematological malignancies. Bone Marrow Transplant (2000) 0.84
Nerve dependency in scarless fetal wound healing. Plast Reconstr Surg (2000) 0.83
Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. Br J Haematol (2005) 0.82
Post transplant lymphoproliferative disorders following reduced intensity conditioning with in vivo T cell depletion. Bone Marrow Transplant (2003) 0.82
Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone Marrow Transplant (2001) 0.82
Clinical trials with CMV-specific T cells. Cytotherapy (2002) 0.81
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? Bone Marrow Transplant (2002) 0.81
Cellular therapy: donor lymphocyte infusion. Curr Opin Hematol (2001) 0.80
Exploiting graft-versus-tumour responses using donor leukocyte infusions. Best Pract Res Clin Haematol (2001) 0.80
Adoptive immunotherapy post bone-marrow transplantation. Blood Rev (1996) 0.80
Patterns of Leydig cell insufficiency in adult males following bone marrow transplantation for haematological malignancies. Bone Marrow Transplant (2001) 0.79
Differential effect of pre-transplant cytoreduction on recovery of day zero host circulating cells. Bone Marrow Transplant (1994) 0.79
Fulminant hepatic failure caused by adenovirus infection following bone marrow transplantation for Hodgkin's disease. Bone Marrow Transplant (1999) 0.78
Successful treatment of autoimmune lymphoproliferative syndrome and refractory autoimmune thrombocytopenic purpura with a reduced intensity conditioning stem cell transplantation followed by donor lymphocyte infusion. Bone Marrow Transplant (2007) 0.78
The use of granulocyte colony-stimulating factor in volunteer blood and marrow registry donors. Bone Marrow Transplant (2006) 0.78
Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms. Bone Marrow Transplant (2009) 0.78
Germ cell damage and Leydig cell insufficiency in recipients of nonmyeloablative transplantation for haematological malignancies. Bone Marrow Transplant (2003) 0.78
Allogeneic transplantation for hepatosplenic alphabeta T-cell lymphoma. Bone Marrow Transplant (2005) 0.76
Bone marrow transplantation for chronic myeloid leukaemia using matched unrelated donors. Bone Marrow Transplant (1989) 0.76
Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusion? Leukemia (2004) 0.76
Syndrome 'X' in adult female recipients of bone marrow transplantation for haematological malignancies. Bone Marrow Transplant (2005) 0.76
Role of allogeneic transplantation in low-grade lymphoma and chronic lymphocytic leukemia. Curr Opin Hematol (2006) 0.76
HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. Br J Haematol (1992) 0.75
Cytomegalovirus infection and disease after autologous peripheral blood stem cell transplantation. Br J Haematol (2001) 0.75
Alloreactive cytotoxic T-cell frequency analysis and HLA matching for bone marrow transplants from HLA matched unrelated donors. Transplant Proc (1989) 0.75
Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex vivo and in vivo T-cell depletion. Bone Marrow Transplant (1993) 0.75
The relevance of nonmyeloablative transplants in developing countries: lessons from the UK experience. Transplant Proc (2003) 0.75
MR angiographic diagnosis of cerebral venous sinus thrombosis following allogeneic bone marrow transplantation. Bone Marrow Transplant (2000) 0.75
Early PCR-negativity after allogeneic BMT in adults with t(4;11) ALL in the absence of acute or chronic GVHD. Bone Marrow Transplant (1999) 0.75
Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. Br J Haematol (1989) 0.75
Simultaneous occurrence of Clostridium difficile and Cytomegalovirus colitis in a recipient of autologous stem cell transplantation. Haematologica (2000) 0.75
One antigen mismatched related donor bone marrow transplant in a patient with acute lymphoblastic leukaemia and beta-thalassaemia major: potential cure of both marrow disorders. Bone Marrow Transplant (2000) 0.75
Bone marrow transplantation for CML. Baillieres Clin Haematol (1987) 0.75
A blood bank audit of elective gynaecological surgery: a case for group and antibody screen. Clin Lab Haematol (1986) 0.75
A fatal case of autoimmune thrombocytopenia with an IgM anti-GPIb/IX following one antigen mismatched unrelated donor bone marrow transplantation. Bone Marrow Transplant (1999) 0.75
Generation of memory T cells for adoptive transfer using clinical-grade anti-CD62L magnetic beads. Bone Marrow Transplant (2016) 0.75
Plasma fibrinolysis during and after normal childbirth. Br J Haematol (1987) 0.75
[Evaluation and management of adult peripheral nerve lesions]. Acta Ortop Mex (2014) 0.75